跳到主要內容

Chacko Jacob 的 Form 4 申報

Oric Pharmaceuticals, Inc.(ORIC),2022/3/25 申報

申報編號
0001209191-22-021153
申報時間
2022/3/25
交易日
2022/3/23-3/25
申報延遲
2 天
10b5-1 計畫
表單沒有這欄(2023 年以前)

這份申報列了 3 筆非衍生性交易。公開市場買進合計 $172.3 萬。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Chacko JacobCIK 0001608936董事、高階主管(總裁、執行長)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2022/3/23Common StockP買進取得+257,127$4.98F1+$1,280,492.46259,779直接
2022/3/24Common StockP買進取得+42,873$5.03F2+$215,651.19302,652直接
2022/3/25Common StockP買進取得+50,000$4.54F3+$227,000352,652直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

Represents the weighted average share price of an aggregate total of 257,127 shares purchased in the price range of $4.73 to $5.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

表 I 有 1 筆交易的價格引用這則附註。

F2

Represents the weighted average share price of an aggregate total of 42,873 shares purchased in the price range of $5.03 to $5.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

表 I 有 1 筆交易的價格引用這則附註。

F3

Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $4.455 to $4.60 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)